Company registration number 12249341 (England and Wales)
RARE DISEASE RESEARCH PARTNERS LTD
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
PAGES FOR FILING WITH REGISTRAR
RARE DISEASE RESEARCH PARTNERS LTD
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 3
RARE DISEASE RESEARCH PARTNERS LTD
BALANCE SHEET
AS AT
31 DECEMBER 2025
31 December 2025
- 1 -
2025
2024
Notes
£
£
£
£
Current assets
Debtors
3
1
1
Net current assets
1
1
Capital and reserves
Called up share capital
1
1

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved and signed by the director and authorised for issue on 27 June 2026
J H Garthwaite
Director
Company registration number 12249341 (England and Wales)
RARE DISEASE RESEARCH PARTNERS LTD
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
- 2 -
1
Accounting policies
Company information

Rare Disease Research Partners Ltd is a private company limited by shares incorporated in England and Wales. The registered office is MPS House, Repton Place, White Lion Road, Amersham, Buckinghamshire, HP7 9LP.

1.1
Basis of preparation

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary a mounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Profit and loss account

The company has not traded during the year or the preceding financial period. During this time, the company received no income and incurred no expenditure and therefore no Profit and loss account is presented in these financial statements.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
0
0
3
Debtors
2025
2024
Amounts falling due after more than one year:
£
£
Amounts owed by group undertakings
1
1
4
Audit report information

As the income statement has been omitted from the filing copy of the financial statements, the following information in relation to the audit report on the statutory financial statements is provided in accordance with s444(5B) of the Companies Act 2006.

The auditor's report is unqualified and includes the following:

RARE DISEASE RESEARCH PARTNERS LTD
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
4
Audit report information
(Continued)
- 3 -
Opinion

In our opinion the financial statements:

- give a true and fair view of the state of the company's affairs as at 31 December 2025 and of its profit for the year then ended;

- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and

- have been prepared in accordance with the requirements of the Companies Act 2006.

Senior Statutory Auditor:
Helen Furlong FCCA
Statutory Auditor:
Xeinadin Audit Limited
Date of audit report:
27 June 2026
5
Parent company

The parent company of Rare Disease Research Partners Ltd is The Society for Mucopolysaccharide Diseases, a registered charity and company registered in England & Wales, by virtue of its 100% shareholding. The ultimate controlling parties of MPS Society is its board of trustees. The registered office for The Society for Mucopolysaccharide Diseases is MPS House, Repton Place, White Lion Road, Amersham, Buckinghamshire, HP7 9LP.

2025-12-31 2025-01-01 false false true 27 June 2026 CCH Software CCH Accounts Production 2026.100 No description of principal activity J H Garthwaite 12249341 2025-01-01 2025-12-31 12249341 2025-12-31 12249341 2024-12-31 12249341 core:ShareCapital 2025-12-31 12249341 core:ShareCapital 2024-12-31 12249341 bus:Director1 2025-01-01 2025-12-31 12249341 2024-01-01 2024-12-31 12249341 core:Non-currentFinancialInstruments 2025-12-31 12249341 core:Non-currentFinancialInstruments 2024-12-31 12249341 bus:EntityHasNeverTraded 2025-01-01 2025-12-31 12249341 bus:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 12249341 bus:SmallCompaniesRegimeForAccounts 2025-01-01 2025-12-31 12249341 bus:FRS102 2025-01-01 2025-12-31 12249341 bus:Audited 2025-01-01 2025-12-31 12249341 bus:FullAccounts 2025-01-01 2025-12-31 xbrli:pure xbrli:shares iso4217:GBP